The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
Site Search
This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.
Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies
Breadth of expertise in business, philanthropy, community engagement, and venture capital to help advance Foundation’s mission
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year
Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science
Human resources veteran Massenburg brings more than 20 years of leadership experience in nonprofit and business sectors
Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab